Buy Generic Roflumilast Online

Generic Roflumilast Information

Introduction

Roflumilast is a phosphodiesterase‑4 (PDE4) inhibitor approved for the long‑term management of severe chronic obstructive pulmonary disease (COPD) in patients with a history of exacerbations. In Hong Kong, COPD remains a leading cause of morbidity, affecting an estimated 5 % of adults over 40 years of age. The medication is also investigated for inflammatory skin disorders such as psoriasis, reflecting its classification within the General health and Skin Care groups. The active compound is roflumilast, marketed internationally under brand names such as Daliresp®. Our online pharmacy supplies the generic version of this drug, offering a therapeutically equivalent and cost‑effective alternative.

What is Roflumilast?

Roflumilast is the generic version of the brand‑name product Daliresp®, which contains the same active compound, roflumilast. The drug was developed by Celgene (now part of Bristol‑Myers Squibb) and received regulatory approval from the US Food and Drug Administration (FDA) in 2011 for COPD. In the European Union and several Asian territories, including Hong Kong, it is authorized under the same indications. Our online pharmacy provides this generic alternative as a cost‑effective treatment option, sourced from licensed manufacturers that meet stringent Good Manufacturing Practice (GMP) standards.

How Roflumilast Works

Roflumilast selectively inhibits the enzyme phosphodiesterase‑4, which is responsible for breaking down cyclic adenosine monophosphate (cAMP) in inflammatory cells. By blocking PDE4, intracellular cAMP concentrations rise, leading to:

• Suppression of pro‑inflammatory cytokines (e.g., tumor necrosis factor‑α, interleukin‑8).
• Reduced activation of neutrophils, macrophages, and T‑lymphocytes.

The net effect is a dampened inflammatory response in the airways, decreasing the frequency and severity of COPD exacerbations. Oral absorption is rapid; peak plasma concentrations occur within 1 h, and a steady‑state is achieved after approximately 4 weeks of daily dosing. The drug’s terminal half‑life is ~20 hours, allowing once‑daily administration. Clearance occurs mainly via hepatic metabolism (CYP3A4 and CYP1A2) with renal excretion of metabolites.

Conditions Treated with Roflumilast

• Severe COPD with a history of exacerbations – The primary approved indication. Clinical trials (e.g., the RECORD trial) demonstrated a 15‑20 % reduction in exacerbation rate versus placebo. In Hong Kong, COPD contributes to ~12 % of all hospital admissions for respiratory disease, making effective prophylaxis essential.
• Chronic bronchitis – As a component of COPD, roflumilast improves symptoms of chronic cough and sputum production.
• Off‑label use in inflammatory skin disorders – Early‑phase studies suggest benefit in plaque psoriasis and atopic dermatitis by modulating skin inflammation. While not yet approved for these conditions in Hong Kong, physicians may consider roflumilast in refractory cases under specialist supervision.

Suitable Candidates for Roflumilast Treatment

• Adults with severe COPD (GOLD stage III/IV) who have experienced at least two moderate exacerbations in the previous year despite optimal bronchodilator therapy.
• Patients already receiving inhaled corticosteroids and long‑acting bronchodilators who require additional systemic anti‑inflammatory control.
• Individuals without uncontrolled infections, severe hepatic impairment (Child‑Pugh C), or known hypersensitivity to roflumilast.
• Patients capable of adhering to a daily oral regimen and who understand the potential for gastrointestinal and neuropsychiatric side effects.

Contra‑indicated or cautionary situations include:

• Active tuberculosis or untreated pneumonia.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²).
• Recent history of major depressive disorder or suicidal ideation; clinicians should monitor mood changes closely.

Risks, Side Effects, and Interactions

Common

• Gastrointestinal upset (nausea, diarrhoea, abdominal pain).
• Weight loss – Often modest (≈ 2–3 kg) over the first few months.
• Headache and dizziness.

Rare

• Elevated liver enzymes (ALT/AST). Routine monitoring is recommended after 3 months of therapy.
• Photosensitivity reactions – Patients should avoid prolonged sun exposure while on treatment.

Serious

• Severe psychiatric events (depression, anxiety, suicidal thoughts). Immediate medical evaluation is required if mood changes occur.
• Severe hypersensitivity (rash, angioedema, anaphylaxis). Discontinue promptly.

Clinically Relevant Drug–Drug Interactions

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase roflumilast plasma concentrations, raising the risk of adverse effects. Dose adjustment or avoidance is advised.
• CYP1A2 inducers (e.g., smoking, carbamazepine) may reduce efficacy.
• Concurrent use with other PDE4 inhibitors (e.g., apremilast) is not recommended due to additive toxicity.

Practical Use: Dosing, Missed Dose, Overdose

• Standard dosing: 500 µg (one tablet) taken orally once daily, preferably in the morning with food to reduce gastrointestinal discomfort.
• Missed dose: If a dose is forgotten within 12 hours, take it as soon as remembered. If more than 12 hours have passed, skip the missed dose and resume the regular schedule; do not double‑dose.
• Overdose: Symptoms may include severe nausea, vomiting, dizziness, and tremor. Seek immediate medical attention; supportive care (e.g., activated charcoal) may be administered. No specific antidote exists.
• Precautions: Avoid alcohol excess, as it may exacerbate gastrointestinal irritation. Patients with hepatic impairment (Child‑Pugh B) should use a reduced dose (250 µg) under medical supervision.

Buying Roflumilast from Our Online Pharmacy

Roflumilast is readily available for purchase from our online pharmacy in Hong Kong. Key advantages include:

• Affordable pricing – We source the generic product near manufacturer cost, translating into lower out‑of‑pocket expenses for patients.
• Verified quality – All batches are imported from GMP‑certified overseas manufacturers and undergo independent quality testing before shipment.
• Guaranteed delivery – Discreet packaging with express shipping (≈ 7 days) or regular airmail (≈ 3 weeks) ensures timely receipt.
• Pharmacy‑broker service – By partnering with licensed overseas pharmacies, we can provide medicines that may not be stocked in local retail outlets, while maintaining strict privacy standards.

Patients seeking a reliable, cost‑effective supply of roflumilast can thus access the medication without compromising on safety or convenience.

FAQ

• Is roflumilast available in both brand‑name and generic forms in Hong Kong?
  Yes. The original brand‑name product is marketed as Daliresp®, while generic roflumilast contains the identical active ingredient and is typically offered at a lower price.

• What does a roflumilast tablet look like?
  Generic tablets are usually white, round, film‑coated, and engraved with “500 µg” or a corresponding imprint indicating the dose strength.

• Can roflumilast be stored in a humid bathroom environment?
  No. The medication should be kept at controlled room temperature (15‑30 °C) away from moisture and direct sunlight. A bathroom cabinet is unsuitable because humidity can degrade the tablet integrity over time.

• Does the drug interact with common over‑the‑counter cough syrups?
  Some cough formulations contain dextromethorphan, which is metabolized by CYP2D6 and does not significantly affect roflumilast. However, syrups containing strong CYP3A4 inhibitors (e.g., certain antihistamines) should be avoided without medical advice.

• Are there any special considerations for travelers taking roflumilast?
  When flying, keep the medication in its original packaging with a copy of the prescription (or a doctor’s letter) to satisfy customs regulations. Maintain the tablets in a carry‑on bag to avoid temperature extremes in cargo holds.

• What is the difference between US and Asian formulations of roflumilast?
  The active ingredient and dosage strength are identical, but excipients (inactive ingredients) may vary slightly to meet regional regulatory standards. These differences seldom affect clinical efficacy but may be relevant for patients with specific allergies.

• Is roflumilast detectable in standard drug‑testing panels?
  Routine employment or sports drug screens do not target PDE4 inhibitors, so roflumilast will not be flagged in standard tests.

• Can roflumilast be taken with herbal supplements such as St. John’s wort?
  St. John’s wort induces CYP3A4, potentially lowering roflumilast plasma levels and reducing therapeutic effect. Patients should discuss any herbal products with their healthcare provider before concurrent use.

• Has roflumilast been evaluated in clinical trials involving Asian populations?
  Subgroup analyses within global Phase III trials (e.g., the ASCENT and MOMENT studies) included Asian participants and demonstrated comparable efficacy and safety profiles to the overall study population.

• What is the mechanism behind roflumilast‑induced weight loss?
  Increased intracellular cAMP may enhance metabolic rate and reduce appetite, leading to modest weight reduction. Monitoring of nutritional status is recommended, especially in frail COPD patients.

• Are there pediatric formulations of roflumilast?
  Currently, roflumilast is approved only for adult use (≥ 18 years). Pediatric safety and dosing have not been established.

• How does roflumilast differ from inhaled corticosteroids for COPD?
  Inhaled corticosteroids target airway inflammation locally, whereas roflumilast provides systemic anti‑inflammatory action via PDE4 inhibition. The two classes are often used together when bronchodilator therapy alone does not sufficiently control exacerbations.

Glossary

Phosphodiesterase‑4 (PDE4)

An enzyme that breaks down cyclic adenosine monophosphate (cAMP) in inflammatory cells; inhibition leads to increased cAMP and reduced inflammation.

Exacerbation (COPD)

A worsening of respiratory symptoms that often requires additional therapy, such as antibiotics or systemic steroids, and may lead to hospitalization.

GMP (Good Manufacturing Practice)

International quality standards that ensure pharmaceutical products are consistently produced and controlled according to quality standards.

eGFR (estimated Glomerular Filtration Rate)

A calculation used to assess kidney function; values below 30 mL/min/1.73 m² indicate severe renal impairment.

⚠️ Disclaimer

The information provided about Roflumilast is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Roflumilast for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.